Comments to the National Committee for Quality Assurance (NCQA) on Hepatitis B as an Adult Immunization Status Measure
The National Committee for Quality Assurance (NCQA) has proposed several changes to the existing Adult Immunization Status (AIS-E) measure, including the addition of a hepatitis B indicator. 

The proposed measure is a positive step towards increasing adult hepatitis B vaccination rates in the U.S. by encouraging providers to recommend the hepatitis B vaccine to all adult patients. 

ORGANIZATION SIGN-ON DEADLINE: Friday, March 8th, 2024 at 5:00pm ET. 

We encourage all partners to use this template to submit their own comments as well. *All comments must be submitted to NCQA by Wednesday, March 13th at 5:00pm ET* 

About AIS-E:
AIS-E assesses the percentage of adults who are up to date on routine vaccinations recommended for adults by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). AIS-E is specified for commercial, Medicaid and Medicare product lines, and uses the HEDIS Electronic Clinical Data Systems (ECDS) reporting standard. This method captures receipt of vaccinations using data from electronic sources, including administrative claims, immunization registries and EHRs. 
Sign in to Google to save your progress. Learn more
(Preview of Letter)

Re: Proposed Changes to Existing Measure for HEDIS® Measurement Year (MY) 2025: Adult Immunization Status – Hepatitis B  

To the National Committee for Quality Assurance: On behalf of the Hepatitis B Foundation, a national non-profit working to improve the lives of those impacted by hepatitis B, and Hep B United, a national coalition of 58 organizations in 27 states dedicated to reducing health disparities associated with hepatitis B, we appreciate the opportunity to comment on the proposed changes to the existing measure for HEDIS MY 2025: Adult Immunization Status (AIS-E).  

The hepatitis B community strongly supports the proposed addition of hepatitis B as a new AIS-E indicator. Hepatitis B remains a significant problem in the U.S., with an estimated 2.4 million individuals living with chronic hepatitis B, and an incidence rate that has grown in recent years due to the opioid epidemic. Although the hepatitis B vaccine has existed for nearly 40 years, just 30% of all adults in the U.S. have been fully vaccinated. We are thrilled that hepatitis B is now a routine immunization, and consider this proposal an opportunity to advance viral hepatitis elimination in the U.S. 

The suggested measure is incredibly timely, as it follows several positive developments in hepatitis B vaccination. In recent years, we have seen the introduction of two new and highly effective hepatitis B vaccines into the U.S. market, the expansion of adult hepatitis B prevention recommendations, and the broadening of hepatitis B vaccine insurance coverage underneath the Inflation Reduction Act. These changes have increased the ability of both patients and providers to access the vaccine and puts the U.S. on a path towards addressing the systemic challenges that have prevented vaccine uptake among adults. The addition of a new AIS-E indicator for hepatitis B further increases access by alerting providers of the new recommendation and encouraging them to offer the vaccine to their patients.  

Read the full comment here. 

To sign on to the letter, please complete the form below.
Feel free to share this form with local coalition partners and other organizations who may be interested in signing on. Please note that this is an organizational support letter.
Organization Name (as you would like it to appear on the letter) *
Type of Organization *
Your Name (for internal use only) *
Your Email Address (for internal use only) *
I am authorized to sign this letter on behalf of my organization *
Required
Feedback/Questions/Comments
Submit
Clear form
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy
Google Forms